. 2019 Apr 2;10:296. doi: 10.3389/fphar.2019.00296
Copyright © 2019 Vitale, Cavalli, Colafrancesco, Priori, Valesini, Argolini, Baldissera, Bartoloni, Cammelli, Canestrari, Sota, Cavallaro, Massaro, Ruscitti, Cipriani, De Marchi, De Vita, Emmi, Ferraccioli, Frassi, Gerli, Gremese, Iannone, Lapadula, Lopalco, Manna, Mathieu, Montecucco, Mosca, Piazza, Piga, Pontikaki, Romano, Rossi, Rossini, Silvestri, Stagnaro, Talarico, Tincani, Viapiana, Vitiello, Galozzi, Sfriso, Gaggiano, Rigante, Dagna, Giacomelli and Cantarini.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
FIGURE 3.
Cumulative DRR of Anakinra in patients with AOSD undergoing their first biologic agent and those previously treated with other biologics.